Founder and CEO of IMMUNE Pharmaceuticals, Grew into a NASDAQ listed company in 3 years. IMMUNE focuses on Antibody Therapeutics with a lead phase II first in class mAb, bertilimumab, for the treatment of inflammatory diseases, including Crohn's and Colitis and Bullous Pemphigoid, an auto-immune orphan disease of the skin. Pipeline includes Amiket, a drug with Orphan Drug Designation for the treatment of Post Herpetic Neurlalgia. Immune is seeking a development and commercialization partner for Amiket. Immune NanomAb platform, developed with the Hebrew University of Jerusalem, is the next generation of "guided therapeutic missiles" targeting specifically cancer cells through a three step ...
We鈥檝e updated our privacy policy so that we are compliant with changing global privacy regulations and to provide you with insight into the limited ways in which we use your data.
You can read the details below. By accepting, you agree to the updated privacy policy.
